HS-10510 / Jiangsu Hansoh Pharma - LARVOL DELTA

THE CLINICAL TRIAL APPROVAL FOR HS-10510 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (Hansoh Pharma Press Release) - "The board of directors...of Hansoh Pharmaceutical Group Company Limited (the 'Company' and together with its subsidiaries, the 'Group') is pleased to announce that, HS-10510 tablets, a Category 1 innovative drug self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for primary hypercholesterolemia and mixed dyslipidemia."

New trial • Dyslipidemia • Metabolic Disorders

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10510 in Healthy Subjects (clinicaltrials.gov) - P1 | N=88 | Not yet recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial • Dyslipidemia • Metabolic Disorders